Marlies Vanden Bempt

Marlies Vanden Bempt

Auto-generated profile, based on publicly available information

Marlies Vanden Bempt

KU Leuven

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2020 in Cell Research
Verified
Journal Article
Closed access
PDF file
JQJunbin Qian
Junbin Qian
SOSiel Olbrecht
Siel Olbrecht
BBBram Boeckx
Bram Boeckx
HVHanne Vos
Hanne Vos
DLDamya Laoui
Damya Laoui
DLDiether Lambrechts
Diether Lambrechts

6 May 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ABAyse Bassez
Ayse Bassez
HVHanne Vos
Hanne Vos
LDLaurien Van Dyck
Laurien Van Dyck
GFGiuseppe Floris
Giuseppe Floris
IAIngrid Arijs
Ingrid Arijs
DLDiether Lambrechts
Diether Lambrechts

30 April 2018 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CBCharles E. de Bock
Charles E. de Bock
SDSofie Demeyer
Sofie Demeyer
SDSandrine Degryse
Sandrine Degryse
DVDelphine Verbeke
Delphine Verbeke
BSBram Sweron
Bram Sweron
JCJan Cools
Jan Cools
Leukemia is caused by the accumulation of multiple genomic lesions in hematopoietic precursor cells. However, how these events cooperate during oncogenic transformation remains poorly understood. We studied the cooperation between activated JAK3/STAT5 signaling and HOXA9 overexpression, two events identified as significantly co-occurring in T-cell acute lymphoblastic leukemia. Expression of mutant JAK3 and HOXA9 led to a rapid development of leukemia originating from multipotent or lymphoid-committed progenitors, with a significant decrease in disease latency compared with JAK3 or HOXA9 alone. Integrated RNA sequencing, chromatin immunoprecipitation sequencing, and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) revealed that STAT5 and HOXA9 have co-occupancy across the genome, resulting in enhanced STAT5 transcriptional activity and ectopic activation of FOS/JUN (AP1). Our data suggest that oncogenic transcription factors such as HOXA9 provide a fertile ground for specific signaling pathways to thrive, explaining why JAK/STAT pathway mutations accumulate in HOXA9-expressing cells. Significance: The mechanism of oncogene cooperation in cancer development remains poorly characterized. In this study, we model the cooperation between activated JAK/STAT signaling and ectopic HOXA9 expression during T-cell leukemia development. We identify a direct cooperation between STAT5 and HOXA9 at the transcriptional level and identify PIM1 kinase as a possible drug target in mutant JAK/STAT/HOXA9-positive leukemia cases. Cancer Discov; 8(5); 616–31. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 517

6 September 2019 in Blood
Verified
Journal Article
Open access
PDF file
MBMichael Broux
Michael Broux
CPCristina Prieto
Cristina Prieto
SDSofie Demeyer
Sofie Demeyer
MBMarlies Vanden Bempt
Marlies Vanden Bempt
LALlucia Alberti-Servera
Llucia Alberti-Servera
JCJan Cools
Jan Cools
Key Points: Suz12 inactivation cooperates with JAK3 mutant signaling to drive T-ALL development. JAK3/Suz12 mutant leukemia cells show increased sensitivity to PI3K/mTOR, VEGF receptor, and HSP90 inhibitors.

1 August 2018 in Cancer Cell
Verified
Journal Article
Open access
MBMarlies Vanden Bempt
Marlies Vanden Bempt
SDSofie Demeyer
Sofie Demeyer
MBMichaël Broux
Michaël Broux
JBJolien De Bie
Jolien De Bie
SBSimon Bornschein
Simon Bornschein
JCJan Cools
Jan Cools
The NUP214-ABL1 fusion is a constitutively activated tyrosine kinase that is significantly associated with overexpression of the TLX1 and TLX3 transcription factors in T cell acute lymphoblastic leukemia (T-ALL). Here we show that NUP214-ABL1 cooperates with TLX1 in driving T-ALL development using a transgenic mouse model and human T-ALL cells. Using integrated ChIP-sequencing, ATAC-sequencing, and RNA-sequencing data, we demonstrate that TLX1 and STAT5, the downstream effector of NUP214-ABL1, co-bind poised enhancer regions, and cooperatively activate the expression of key proto-oncogenes such as MYC and BCL2. Inhibition of STAT5, downregulation of TLX1 or MYC, or interference with enhancer function through BET-inhibitor treatment leads to reduction of target gene expression and induction of leukemia cell death.

28 June 2017 in Haematologica
Verified
Journal Article
Open access
PDF file
JKJo-Anne van der Krogt
Jo-Anne van der Krogt
MBMarlies Vanden Bempt
Marlies Vanden Bempt
JFJulio Finalet Ferreiro
Julio Finalet Ferreiro
NMNicole Mentens
Nicole Mentens
KJKris Jacobs
Kris Jacobs
IWIwona Wlodarska
Iwona Wlodarska
ALK positive anaplastic large cell lymphoma is characterized by 2p23/ALK aberrations, including the classic t(2;5)(p23;q35)/NPM1-ALK rearrangement present in ~80% of cases and several variant t(2p23/ALK) occurring in the remaining cases. The ALK fusion partners play a key role in the constitutive activation of the chimeric protein and its subcellular localization. Using various molecular technologies, we have characterized ALK fusions in eight recently diagnosed anaplastic large cell lymphoma cases with cytoplasmic-only ALK expression. The identified partner genes included EEF1G (one case), RNF213/ALO17 (one case), ATIC (four cases) and TPM3 (two cases). Notably, all cases showed copy number gain of the rearranged ALK gene, which is never observed in NPM1-ALK-positive lymphomas. We hypothesized that this could be due to lower expression levels and/or lower oncogenic potential of the variant ALK fusions. Indeed, all partner genes, except EEF1G, showed lower expression in normal and malignant T cells, in comparison with NPM1. In addition, we investigated the transformation potential of endogenous Npm1-Alk and Atic-Alk fusions generated by CRISPR/Cas9 genome editing in Ba/F3 cells. We found that Npm1-Alk has a stronger transformation potential than Atic-Alk, and we observed a subclonal gain of Atic-Alk after a longer culture period, which was not observed for Npm1-Alk. Taken together, our data illustrate that lymphomas driven by the variant ATIC-ALK fusion (and likely by RNF213-ALK, and TPM3-ALK), but not the classic NPM1-ALK, require an increased dosage of the ALK hybrid gene to compensate for the relatively low and insufficient expression and signaling properties of the chimeric gene.